



PHG COVID-19 Update: April 27

Dear Valued Providers

We want to be a resource to our Premier Health Group Independent providers. In recent days, the clinical information regarding COVID-19 has begun to slow down. Due to this, we will be decreasing the frequency of the publication.

In addition, we have created a resources page on the [PHG website](#).

Please feel free to contact us directly at **(937) 499-7441** with any questions you might have or if you would like to speak with our Medical Director, Scott Swabb, DO.

Yours sincerely,

Renee George
President, Premier Health Group

IN THIS ISSUE

Telehealth Webinar: Thursday, April 30

Premier inpatient physicians and providers

CMS to pay providers via MIPS for participating in COVID-19 drug treatment trials

Telehealth Webinar: Thursday, April 30

Join **David Kelly, Director of Revenue Cycle, Premier Physician Network** and **Scott Swabb, DO, Premier Health Group Medical Director** for an informative session on the latest telehealth billing and coding guidelines.

Thursday, April 30

5:00 to 6:00 p.m.

[+1 937-401-2803](#) United States, Dayton (Toll)

[\(877\) 287-6804](#) United States (Toll-free)

Conference ID: 488 965 937#

The remaining topics for the educational series will include:

1. COVID treatment options
2. Ramping up operations again

Additional information will be provided on the remaining topics when available.

Premier Inpatient Physicians and Providers: Update on Pure Healthcare Inpatient Services - Out of an abundance of caution, and in collaboration with Pure Healthcare, a process has been developed by which Pure Healthcare will be able to serve inpatients who require palliative care via a bi-directional audio/video platform. This will allow their team - if needed - to continue providing safe and effective care via telehealth. [Find out more.](#)



CMS to pay providers via MIPS for participating in COVID-19 drug treatment trials

The current administration announced that the Center for Medicare and Medicaid Services (CMS), will give providers credit under the Merit-based Incentive Payment System (MIPS) for participating in COVID-19 clinical trials.

The goal of this initiative is to provide data that will assist in providing treatments for combating COVID-19. **To receive credit for the MIPS COVID-19 clinical trials:**

- Clinicians must attest that they participated in a COVID-19 clinical trial utilizing a drug or biological product to treat a patient with a COVID-19 infection under CPT code 87635 (Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique).
- Providers must also report their findings through a clinical data registry or a clinical data repository for the duration of the study.

Participation in clinical trials will carry a high weight in the MIPS improvement activities performance category.